|
Friday, November 18, 2016
Print Current Session:
 |
|
|
Friday
SESSION 84:
NEW DEVELOPMENTS AND UPDATES REGARDING CCSVI IN MULTIPLE SCLEROSIS; USE OF DRUGS IN VASCULAR DISEASE PATIENTS AND WAYS TO PREDICT RISKS OF ADVERSE EVENTS
Moderators:Caron B. Rockman, MD / Russell H. Samson, MD, RVT, FACS
|
|
| SESSION 84 SCHEDULE | |
| CCSVI | |
| 2:08 PM - 2:13 PM | Multicenter Blinded RCT To Determine Safety And Effectiveness (Quality Of Life) Of Venous PTA For Multiple Sclerosis (The BRAVE DREAMS Trial): Design And Progress: Will It Settle The Controversy |
| Presenter(s):Paolo Zamboni, MD | |
| View Slides in PDF | |
| DRUG TREATMENT OF VASCULAR DISEASES | |
| 2:14 PM - 2:19 PM | How Can Statins And Other Medical Treatment Decrease The Amputation And Major Adverse Limb Event Rates After Revascularizations For CLI: What Are The Optimal Drugs And Dosages |
| Presenter(s):Patrick A. Stone, MD / Aravinda Nanjundappa, MD | |
| View Slides in PDF | |
| 2:20 PM - 2:25 PM | Optimal Use Of ACE Inhibitors, Cilostazol, And Statins In Patients Undergoing Open And Endovascular Procedures |
| Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
| View Slides in PDF | |
| 2:26 PM - 2:31 PM | Update On When And How Should Beta Blockers Be Used In Low Risk And High Risk Vascular Patients Generally And When They Undergo Operations And Interventions: Dosage Is Key |
| Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
| View Slides in PDF | |
| 2:32 PM - 2:37 PM | Improving Non-Coronary Stent Outcomes By Pharmacological Manipulations – 2C19 And Plavix: How Do They Do It |
| Presenter(s):Karthikeshwar Kasirajan, MD | |
| View Slides in PDF | |
| 2:38 PM - 2:43 PM | What Is New In Antiplatelet Treatment Of Vascular Patients: Which Drugs In Which Situation: New Drugs And What Does The EUCLID Trial Tell Us |
| Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Caron B. Rockman, MD | |
| View Slides in PDF | |
| 2:44 PM - 2:50 PM | Panel Discussion |
| Moderator(s): Anthony J. Comerota, MD, FACS, FACC / Elliot L. Chaikof, MD, PhD | |
| 2:50 PM - 2:55 PM | Benefits Of Perioperative Statins In Improving Outcomes And Decreasing Adverse Events After AAA And Carotid Procedures – Endo And Open: Optimal Timing, Drug And Dosage |
| Presenter(s):Bruce A. Perler, MD, MBA | |
| View Slides in PDF | |
| 2:56 PM - 3:01 PM | Update On The Medical (Drug) Treatment Of AAA Disease: What Does Metformin Do: Does Any Drug Slow AAA Growth |
| Presenter(s):Ronald L. Dalman, MD | |
| View Slides in PDF | |
| 3:02 PM - 3:07 PM | Should Bivalirudin Replace Heparin In Non-Cardiac Interventions: Advantages And How To Use It |
| Presenter(s):George H. Meier III, MD | |
| View Slides in PDF | |
| VALUE OF TESTS | |
| 3:08 PM - 3:13 PM | Biomarkers Can Predict Long-Term (~10 Years) Adverse Cardiovascular Events In Vascular Patients: Which Ones And How Can They Be Used |
| Presenter(s):Beatrice R. Amann-Vesti, MD | |
| View Slides in PDF | |
| 3:14 PM - 3:19 PM | How To Identify Patients At Risk Of Cardiovascular Adverse Events After EVAR |
| Presenter(s):Janet T. Powell, MD, PhD | |
| View Slides in PDF | |
| 3:20 PM - 3:26 PM | Panel Discussion |
| 3:26 PM - 3:36 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 84 | |
| previous | next |